Inhibition of p53 and/or AKT as a new therapeutic approach specifically targeting ALT cancers

While the majority of all human cancers counteract telomere shortening by expressing telomerase, ~15% of all cancers maintain telomere length by a telomerase-independent mechanism known as alternative lengthening of telomeres (ALT). Here, we show that high load of intrinsic DNA damage is present in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Yuanlong, Wu, Shu, Zhang, Zepeng, Li, Xiaocui, Li, Feng, Yan, Siyu, Liu, Haiying, Huang, Junjiu, Zhao, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834538/
https://www.ncbi.nlm.nih.gov/pubmed/31115790
http://dx.doi.org/10.1007/s13238-019-0634-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834538/
https://www.ncbi.nlm.nih.gov/pubmed/31115790
http://dx.doi.org/10.1007/s13238-019-0634-z

Ejemplares similares